Prakash Chandra, Wang Weiwei, O'Connell Thomas, Johnson Kim A
Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton, Connecticut, USA.
Drug Metab Dispos. 2008 Oct;36(10):2093-103. doi: 10.1124/dmd.108.022897. Epub 2008 Jul 24.
CP-533,536, (3-{[(4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (1), an EP2 receptor-selective prostaglandin E2 agonist, is being developed to aid in the healing of bone fractures. To support the development of this program, in vitro metabolism of 1 was investigated in human liver microsomes and major recombinant human cytochrome P450 (P450) isoforms. 1 was metabolized in vitro by at least three recombinant human P450s: CYP3A4, CYP3A5, and CYP2C8. The turnover of 1 was NADPH-dependent and was completely inhibited by ketoconazole and quercetin in the CYP3A4/5 and CYP2C8 incubations, respectively. The major metabolic pathways were caused by oxidation of the tert-butyl moiety to form the omega-hydroxy metabolite (M4), oxidation of the pyridine moiety, and/or N-dealkylation of the methylphenoxy acetic acid moiety. The alcohol metabolite M4 was further oxidized to the corresponding carboxylic acid M3. In addition to these pathways, three unusual metabolites (M22, M23, and M26) resulting from C-demethylation of the tert-butyl group were identified using high-resolution liquid chromatography/tandem mass spectrometry and liquid chromatography/mass spectrometry/NMR. The C-demethylated metabolites were not detected on incubation of carboxylic acid metabolite M3 with either human liver microsomes or CYP3A/2C8 isoforms, suggesting that these metabolites were not derived from decarboxylation of M3. A possible mechanism for C-demethylation may involve the oxidation of M4 to form an aldehyde metabolite (M24), followed by P450-mediated deformylation, to give an unstable carbon-centered radical and formic acid. The carbon-centered radical intermediate then undergoes either oxygen rebound to form an alcohol metabolite M23 or hydrogen abstraction leading to an olefin metabolite M26.
CP-533,536,即(3-{[(4-叔丁基苄基)-(吡啶-3-磺酰基)-氨基]-甲基}-苯氧基)乙酸(1),一种EP2受体选择性前列腺素E2激动剂,正被开发用于促进骨折愈合。为支持该项目的开展,对1在人肝微粒体和主要重组人细胞色素P450(P450)同工酶中的体外代谢进行了研究。1在体外至少被三种重组人P450代谢:CYP3A4、CYP3A5和CYP2C8。1的周转是NADPH依赖性的,在CYP3A4/5和CYP2C8孵育中分别被酮康唑和槲皮素完全抑制。主要代谢途径是叔丁基部分氧化形成ω-羟基代谢物(M4)、吡啶部分氧化和/或甲基苯氧基乙酸部分的N-脱烷基化。醇代谢物M4进一步氧化为相应的羧酸M3。除了这些途径外,还使用高分辨率液相色谱/串联质谱和液相色谱/质谱/NMR鉴定了三种由叔丁基C-去甲基化产生的不寻常代谢物(M22、M23和M26)。羧酸代谢物M3与人肝微粒体或CYP3A/2C8同工酶孵育时未检测到C-去甲基化代谢物,这表明这些代谢物不是由M3脱羧产生的。C-去甲基化的一种可能机制可能涉及M4氧化形成醛代谢物(M24),随后由P450介导的脱甲酰化,生成不稳定的碳中心自由基和甲酸。碳中心自由基中间体然后经历氧反弹形成醇代谢物M23或氢提取导致烯烃代谢物M26。